Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical firms, like the makers of Xarelto, have a duty to make sure that their drugs are reasonably protected for use – and failure to perform so may be grounds for compensation. Our lawyers are working tough to obtain those hurt by the drug the compensation they may be entitled to.
Even though bleeding can be a widespread complication associated with anticoagulants, it has been alleged that Xarelto is far more hazardous than classic blood thinners because no antidote exists to reverse its blood-thinning effects. This signifies that, inside the occasion of an emergency, sufferers might be at risk for irreversible bleeding issues, like life-threatening internal and gastrointestinal hemorrhaging.
In case you or possibly a loved 1 suffered a severe bleeding occasion after taking Xarelto, you may have legal recourse. For a lot more data, make contact with us today to possess your case reviewed, free of charge of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are seeking compensation from Bayer and Janssen for past and future healthcare bills, lost wages, pain and suffering and, in instances of death, funeral expenses. Furthermore, they are looking for punitive damages, that are typically awarded to punish the defendant and deter other businesses from acting similarly.
Why Are Lawsuits Becoming Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is xarelto an anticoagulant hazardous and defective. The plaintiffs claim that, unlike standard anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective signifies of stopping Xarelto users from bleeding within the event of an emergency. Plaintiffs inside the lawsuits allege critical and fatal injuries, such as cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior inside the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user inside the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to severe bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting.
Visit this page for far more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.